BioVie prices $3M public offering of 1.96M units at $1.53/share with warrants

BIOVIE INC.

Gross proceeds ~$3M from 1,960,800 units at $1.53 each; each unit includes share or pre-funded warrant plus 5-year warrant exercisable at $1.53.
Offering expected to close September 25, 2024; ThinkEquity acting as sole placement agent.
Net proceeds to be used for working capital and general corporate purposes.
BioVie is a clinical-stage company focused on liver disease and neurodegenerative disorders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.